Zhi Tong Cai Jing·2025-08-27 01:33Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) has seen a significant increase in stock price, rising by 6.23% to HKD 16.37, following the announcement of a potential exclusive agency agreement for its core product TY-9591 with Sichuan Huiyu Pharmaceutical's subsidiary, Sichuan Huichenxing [1] Group 1 - The company plans to appoint Sichuan Huichenxing as the exclusive agent for TY-9591 in mainland China, excluding Hong Kong, Macau, Taiwan, and other overseas regions [1] - The initial milestone payment for this potential agency agreement could reach up to RMB 150 million [1] - The company is entering the commercialization phase for TY-9591, and the agreement is expected to leverage Sichuan Huiyu's extensive sales and agency network [1] Group 2 - Sichuan Huiyu is a mature pharmaceutical enterprise with a complete industrial chain and rich experience in drug agency and sales in China [1] - The arrangement is anticipated to enhance sales and revenue for TY-9591, accelerate market penetration, and reduce the costs associated with establishing new sales channels [1] - Collaborating with a well-known pharmaceutical company is expected to strengthen the company's brand image [1]